Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Nichols

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
American Heart Journal|August 5, 2000
Effect of sex, hemodynamics, body size, and other clinical variables on the corrected thrombolysis in myocardial infarction frame count used as an assessment of coronary blood flowB A Faile, J A Guzzo, D A Tate, et al.
Thrombosis and Haemostasis|August 26, 2000
Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colonyR W Herzog, V R Arruda, T H Fisher, et al.
Mayo Clinic Proceedings|July 1, 1991
von Willebrand factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosisK M Brinkhous, R L Reddick, M S Read, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 21, 2011
Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogsD M Karpf, M Kjalke, L Thim, et al.
Circulation Research|November 26, 1999
Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signalingT C Nichols, T du Laney, B Zheng, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2011
Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dogT Knudsen, A T Kristensen, T C Nichols, et al.
Journal of Thrombosis and Haemostasis : JTH|April 7, 2012
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogsT C Nichols, H W G Franck, C T Franck, et al.
Thrombosis and Haemostasis|June 1, 2002
Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeysK McCarthy, P Stewart, J Sigman, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|April 1, 1993
Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a)J K Williams, D A Bellinger, T C Nichols, et al.
Antisense & Nucleic Acid Drug Development|January 26, 1999
Failure to achieve gene conversion with chimeric circular oligonucleotides: potentially misleading PCR artifacts observedZ Zhang, M Eriksson, G Falk, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
American Heart Journal|August 5, 2000
Effect of sex, hemodynamics, body size, and other clinical variables on the corrected thrombolysis in myocardial infarction frame count used as an assessment of coronary blood flowB A Faile, J A Guzzo, D A Tate, et al.
Thrombosis and Haemostasis|August 26, 2000
Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colonyR W Herzog, V R Arruda, T H Fisher, et al.
Mayo Clinic Proceedings|July 1, 1991
von Willebrand factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosisK M Brinkhous, R L Reddick, M S Read, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 21, 2011
Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogsD M Karpf, M Kjalke, L Thim, et al.
Circulation Research|November 26, 1999
Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signalingT C Nichols, T du Laney, B Zheng, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2011
Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dogT Knudsen, A T Kristensen, T C Nichols, et al.
Journal of Thrombosis and Haemostasis : JTH|April 7, 2012
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogsT C Nichols, H W G Franck, C T Franck, et al.
Thrombosis and Haemostasis|June 1, 2002
Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeysK McCarthy, P Stewart, J Sigman, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|April 1, 1993
Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a)J K Williams, D A Bellinger, T C Nichols, et al.
Antisense & Nucleic Acid Drug Development|January 26, 1999
Failure to achieve gene conversion with chimeric circular oligonucleotides: potentially misleading PCR artifacts observedZ Zhang, M Eriksson, G Falk, et al.
Pageof 6